Tag: NASDAQ: SLS

Business

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) Drops 15% After Announcing Galinpepimut Combination with Pembrolizumab Study Data

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) dropped 15.07% after the company released initial immunobiological and clinical data from the phase1/2 clinical study with its flagship candidate galinpepimut-S (GPS) in combination with pembrolizumab. GPS is the SELLAS’ Wilms Tumor-1 targeting peptide treatment.  The study conducted in collaboration with Merck The […]

Business

Sellas Life Sciences Group Inc (NASDAQ: SLS) Reports Heartening Updated Scientific Statistics

Sellas Life Sciences Group Inc (NASDAQ: SLS) today announced heartening restructured scientific statistics from a Phase 1 investigator-sponsored scientific pilot of its foremost scientific applicant, galinpepimut-S (GPS). The applicant united with the checkpoint inhibitor nivolumab (Opdivo®) in patients with macroscopic deposits of malevolent pleural mesothelioma. The reading particulars are as […]